Acumen Pharmaceuticals Q4 EPS $(0.29) Misses $(0.26) Estimate
Portfolio Pulse from Happy Mohamed
Acumen Pharmaceuticals (NASDAQ:ABOS) reported Q4 earnings with losses of $(0.29) per share, missing the consensus estimate of $(0.26) by 11.54%. This represents a 9.38% improvement over the previous year's losses of $(0.32) per share.
March 26, 2024 | 1:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Acumen Pharmaceuticals reported a Q4 EPS loss of $(0.29), missing estimates by 11.54% but showing a 9.38% improvement YOY.
Missing the consensus estimate typically leads to negative investor sentiment in the short term, potentially causing a decrease in stock price. However, the improvement over the previous year's losses may mitigate some negative impact.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100